Lilly Has A Couple Of Controversies To Cover During Earnings Call

 
• By Mandy Jackson

Q1 Earnings Preview: From troubling safety data for tanezumab to pressure on insulin prices, Lilly is likely to face questions about controversies in its R&D pipeline and commercial portfolio during its first quarter earnings call on April 30. 

Quarterly resluts on typewriter close up
Lilly's Q1 earnings will be released 30 April

More from Earnings

More from Business